CPX-351 Plus Quizartinib

A Phase I/II Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Quizartinib in Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)

Arms / Cohorts

Experimental:Frontline Cohort: CPX-351 + Quizartinib

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental:Relapsed or Refractory Cohort: CPX-351 + Quizartinib

Status
Status not available
Overview
Overview not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Patient Screener(888) 803-1766

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.